"Neoplasms, Basal Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neoplasms composed of cells from the deepest layer of the epidermis. The concept does not refer to neoplasms located in the stratum basale.
| Descriptor ID |
D018295
|
| MeSH Number(s) |
C04.557.470.565
|
| Concept/Terms |
Neoplasms, Basal Cell- Neoplasms, Basal Cell
- Basal Cell Neoplasms
- Basal Cell Neoplasm
- Cell Neoplasm, Basal
- Cell Neoplasms, Basal
- Neoplasm, Basal Cell
Basal Cell Cancer- Basal Cell Cancer
- Basal Cell Cancers
- Cancer, Basal Cell
- Cancers, Basal Cell
- Cell Cancer, Basal
- Cell Cancers, Basal
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms, Basal Cell".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Basal Cell".
This graph shows the total number of publications written about "Neoplasms, Basal Cell" by people in this website by year, and whether "Neoplasms, Basal Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasms, Basal Cell" by people in Profiles.
-
Neuroendocrine prostate carcinoma cells originate from the p63-expressing basal cells but not the pre-existing adenocarcinoma cells in mice. Cell Res. 2019 05; 29(5):420-422.
-
Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine. 2016 Oct; 12:105-117.
-
Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Breast Cancer Res Treat. 2015 Jul; 152(2):347-56.
-
Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling. PLoS One. 2015; 10(5):e0127678.
-
a-catenin acts as a tumour suppressor in E-cadherin-negative basal-like breast cancer by inhibiting NF-?B signalling. Nat Cell Biol. 2014 Mar; 16(3):245-54.
-
Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A. 2014 Feb 04; 111(5):E592-600.
-
Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. Clin Cancer Res. 2014 Jan 15; 20(2):404-12.
-
Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models. Mol Cancer Ther. 2013 Aug; 12(8):1665-75.
-
ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Res. 2012 Nov 16; 14(6):R148.
-
Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):331-45.